Sprint Bioscience Revenue vs. Cash And Equivalents
| SPRINT Stock | SEK 1.71 0.11 6.04% |
For Sprint Bioscience profitability analysis, we use financial ratios and fundamental drivers that measure the ability of Sprint Bioscience to generate income relative to revenue, assets, operating costs, and current equity. These fundamental indicators attest to how well Sprint Bioscience AB utilizes its assets to generate profit and value for its shareholders. The profitability module also shows relationships between Sprint Bioscience's most relevant fundamental drivers. It provides multiple suggestions of what could affect the performance of Sprint Bioscience AB over time as well as its relative position and ranking within its peers.
Sprint |
Sprint Bioscience Cash And Equivalents vs. Revenue Fundamental Analysis
Comparative valuation techniques use various fundamental indicators to help in determining Sprint Bioscience's current stock value. Our valuation model uses many indicators to compare Sprint Bioscience value to that of its competitors to determine the firm's financial worth. Sprint Bioscience AB is currently regarded number one company in revenue category among its peers. It also is currently regarded as top stock in cash and equivalents category among its peers creating about 0.39 of Cash And Equivalents per Revenue. The ratio of Revenue to Cash And Equivalents for Sprint Bioscience AB is roughly 2.54 . Comparative valuation analysis is a catch-all model that can be used if you cannot value Sprint Bioscience by discounting back its dividends or cash flows. This model doesn't attempt to find an intrinsic value for Sprint Bioscience's Stock. Still, instead, it compares the stock's price multiples to a benchmark or nearest competition to determine if the stock is relatively undervalued or overvalued.Sprint Revenue vs. Competition
Sprint Bioscience AB is currently regarded number one company in revenue category among its peers. Market size based on revenue of Drug Manufacturers - Specialty & Generic industry is at this time estimated at about 52.91 Million. Sprint Bioscience totals roughly 35.11 Million in revenue claiming about 66% of equities under Drug Manufacturers - Specialty & Generic industry.
Sprint Cash And Equivalents vs. Revenue
Revenue is income that a firm generates from business activities such us rendering services or selling goods to customers. It is a crucial part of a business and an essential item when evaluating a company's financial statements. Revenues from a firm's primary business operations can be reported on the income statement as sales revenue, net sales, or simply sales, depending on the industry in which a given company operates.
Sprint Bioscience |
| = | 35.11 M |
Revenue is typically recorded when cash or cash equivalents are exchanged for services or goods and can include products or services discounts, promotions, as well as early payments on invoices or services rendered in advance.
Cash or Cash Equivalents are the most liquid of all assets found on the company's balance sheet. It is used in calculating many of the firm's liquidity ratios and is a good indicator of the overall financial health of a company. Companies with a lot of cash are usually attractive takeover targets. Cash Equivalents are balance sheet items that are typically reported using currency printed on notes.
Sprint Bioscience |
| = | 13.82 M |
Cash equivalents represent current assets that are easily convertible to cash such as short term bonds, savings account, money market funds, or certificate of deposits (CDs). One of the important consideration companies make when classifying assets as cash equivalent is that investments they report on their balance sheets under current assets should have almost no risk of change in value over the next few months (usually three months).
Sprint Cash And Equivalents Comparison
Sprint Bioscience is currently under evaluation in cash and equivalents category among its peers.
Sprint Bioscience Profitability Projections
The most important aspect of a successful company is its ability to generate a profit. For investors in Sprint Bioscience, profitability is also one of the essential criteria for including it into their portfolios because, without profit, Sprint Bioscience will eventually generate negative long term returns. The profitability progress is the general direction of Sprint Bioscience's change in net profit over the period of time. It can combine multiple indicators of Sprint Bioscience, where stable trends show no significant progress. An accelerating trend is seen as positive, while a decreasing one is unfavorable. A rising trend means that profits are rising, and operational efficiency may be rising as well. A decreasing trend is a sign of poor performance and may indicate upcoming losses.
Sprint Bioscience AB develops pharmaceutical products in the areas of cancer and metabolism. Sprint Bioscience AB was founded in 2009 and is based in Huddinge, Sweden. Sprint Bioscience operates under Pharmaceuticals And Biosciences classification in Sweden and is traded on Stockholm Stock Exchange.
Sprint Profitability Driver Comparison
Profitability drivers are factors that can directly affect your investment outlook on Sprint Bioscience. Investors often realize that things won't turn out the way they predict. There are maybe way too many unforeseen events and contingencies during the holding period of Sprint Bioscience position where the market behavior may be hard to predict, tax policy changes, gold or oil price hikes, calamities change, and many others. The question is, are you prepared for these unexpected events? Although some of these situations are obviously beyond your control, you can still follow the important profit indicators to know where you should focus on when things like this occur. Below are some of the Sprint Bioscience's important profitability drivers and their relationship over time.
Use Sprint Bioscience in pair-trading
One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if Sprint Bioscience position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Sprint Bioscience will appreciate offsetting losses from the drop in the long position's value.Sprint Bioscience Pair Trading
Sprint Bioscience AB Pair Trading Analysis
The ability to find closely correlated positions to Sprint Bioscience could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace Sprint Bioscience when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back Sprint Bioscience - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling Sprint Bioscience AB to buy it.
The correlation of Sprint Bioscience is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as Sprint Bioscience moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if Sprint Bioscience moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Correlation analysis and pair trading evaluation for Sprint Bioscience can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.Use Investing Themes to Complement your Sprint Bioscience position
In addition to having Sprint Bioscience in your portfolios, you can quickly add positions using our predefined set of ideas and optimize them against your very unique investing style. A single investing idea is a collection of funds, stocks, ETFs, or cryptocurrencies that are programmatically selected from a pull of investment themes. After you determine your investment opportunity, you can then find an optimal portfolio that will maximize potential returns on the chosen idea or minimize its exposure to market volatility.Did You Try This Idea?
Run Financials ETFs Thematic Idea Now
Financials ETFs
ETF themes focus on helping investors to gain exposure to a broad range of assets, diversify, and lower overall costs. The Financials ETFs theme has 45 constituents at this time.
You can either use a buy-and-hold strategy to lock in the entire theme or actively trade it to take advantage of the short-term price volatility of individual constituents. Macroaxis can help you discover thousands of investment opportunities in different asset classes. In addition, you can partner with us for reliable portfolio optimization as you plan to utilize Financials ETFs Theme or any other thematic opportunities.
| View All Next | Launch |
Other Information on Investing in Sprint Stock
To fully project Sprint Bioscience's future profitability, investors should examine all historical financial statements. These statements provide investors with a comprehensive snapshot of the financial position of Sprint Bioscience at a specified time, usually calculated after every quarter, six months, or one year. Three primary documents fall into the category of financial statements. These documents include Sprint Bioscience's income statement, its balance sheet, and the statement of cash flows.